Skip to main content
QuestionsResearchTagsGuidelinesLeaderboard
tachyDx Research Portal

Research tagged [hematology]

Every paper is generated from a real clinical discussion on tachyDx, peer-reviewed by verified physicians, and published with a unique TDX identifier. All contributors are credited.

DOIs registered viaCrossref
Published26Under ReviewFlagged
Clear filters

3 papers

TDX-2026-00026

Low-Titer Group O Whole Blood Resuscitation in Civilian Massive Hemorrhage: An Evidence Synthesis and Implementation Review

Massive hemorrhage remains a leading cause of preventable death in trauma. Traditional resuscitation protocols, often based on 1:1:1 component therapy (packed red blood cells, fresh frozen plasma, platelets), aim to mitigate trauma-induced coagulopathy. However, logistical challenges and delays associated with component preparation have prompted exploration of alternative strategies. Low-titer group O whole blood (LTOWB) has emerged as a promising option, offering a physiologically balanced resuscitation product. This paper synthesizes expert clinical perspectives and recent trial data regarding the transition to LTOWB in civilian trauma centers. Findings indicate that a hybrid approach, utilizing LTOWB for initial resuscitation units, can accelerate balanced resuscitation and improve hemostatic parameters. While logistical hurdles such as shelf life and inventory management persist, strategies for mitigation have been developed. Furthermore, LTOWB significantly reduces administrative errors and simplifies resuscitation protocols in high-stress environments. The role of dried plasma as a pre-hospital adjunct, particularly in settings with prolonged transport times or challenging cold chain logistics, is also discussed. The collective evidence suggests that LTOWB represents a valuable advancement in massive hemorrhage resuscitation, warranting careful consideration for integration into institutional protocols.

A physician-only Q&A platform where verified medical doctors share clinical knowledge, debate evidence, and build the knowledge base the world needs.

Powered by

Platform

  • Questions
  • Research
  • Tags
  • Guidelines
  • Leaderboard
  • Report a Bug

Ecosystem

  • Teams
  • Sponsors
  • Hiring
  • Publishing
  • CME
  • Data

Company

  • About
  • Support
  • Privacy Policy
  • Terms of Service
  • Contact

© 2026 Aethryva Deeptech Pvt Ltd. All rights reserved.

Crossref Member
2 contributors 82 votes 9 Apr 2026

TDX-2026-00024

Optimal Sequencing of Immunotherapy for Pediatric B-Cell Acute Lymphoblastic Leukemia with Second Relapse Post-Allogeneic Hematopoietic Stem Cell Transplantation: A Clinical Consensus

Pediatric B-cell acute lymphoblastic leukemia (B-ALL) with second relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents a highly challenging clinical scenario with limited curative options. This paper synthesizes expert clinical opinion regarding the optimal sequencing and selection of novel immunotherapies, specifically tisagenlecleucel (CAR-T cell therapy) and blinatumomab (CD19/CD3 bispecific T-cell engager), for a 6-year-old female presenting with a second marrow relapse 14 months post-transplant. The discussion addresses critical considerations including blast burden management, manufacturing timelines, and potential toxicities in a heavily pre-treated patient. A consensus emerged favoring a strategy of bridging with blinatumomab to reduce blast burden, followed by definitive tisagenlecleucel. This approach leverages the immediate availability and debulking potential of blinatumomab to optimize conditions for CAR-T cell therapy, which offers superior long-term remission rates. The paper also explores the role of inotuzumab ozogamicin and discusses logistical challenges in diverse healthcare settings. This synthesis provides practical guidance for clinicians navigating complex treatment decisions in this ultra-high-risk patient population, emphasizing evidence-based sequencing to maximize therapeutic efficacy and minimize adverse events.

2 contributors 65 votes 9 Apr 2026

TDX-2026-00004

Anticoagulation Strategies for Portal Vein Thrombosis in Cirrhotic Patients: A Community Peer-Reviewed Clinical Consensus

Background: Portal vein thrombosis (PVT) is a common complication of cirrhosis, significantly impacting patient outcomes and transplant candidacy. The management of PVT in cirrhotic patients is complex due to a rebalanced hemostatic system, making traditional coagulation parameters unreliable and raising concerns about both bleeding and thrombotic risks. This paper synthesizes expert opinions on anticoagulation strategies for incidental PVT in Child-Pugh B cirrhosis. Methods: This study leveraged a community peer-review platform, tachyDx, where a clinical scenario involving a 52-year-old male with Child-Pugh B cirrhosis and incidental main PVT was presented. Three verified specialist physicians contributed detailed responses, which were further peer-voted by 68 community members. The discussion focused on INR interpretation, choice of anticoagulant, duration of therapy, and indications for transjugular intrahepatic portosystemic shunt (TIPS). Results: Expert consensus highlighted that INR is an unreliable marker of hemostasis in cirrhosis, advocating for clinical assessment and potentially viscoelastic testing. Low molecular weight heparin (LMWH) was preferred over direct oral anticoagulants (DOACs) in Child-Pugh B cirrhosis due to limited safety data and hepatic metabolism concerns, with specific platelet count-based dosing recommendations. Anticoagulation for at least 6 months, or until liver transplant, was recommended for main PVT. TIPS was reserved for failed anticoagulation or complications of portal hypertension. The importance of ruling out pylephlebitis was also emphasized. Conclusions: The management of PVT in cirrhotic patients necessitates a nuanced, multidisciplinary approach. LMWH appears to be the preferred initial anticoagulant in Child-Pugh B cirrhosis, guided by clinical factors and platelet counts. Further research, particularly randomized controlled trials, is warranted to establish the long-term safety and efficacy of DOACs in this vulnerable population.

3 contributors 68 votes 6 Apr 2026
Page 1 of 2Next →

Topics

Allpharmacology8critical-care7cardiology6emergency-medicine6oncology5pulmonology5nephrology4neurology4gastroenterology3immunology3hematology3surgery3infectious-disease3radiology2endocrinology2anesthesiology2hepatology2pediatrics2rheumatology2evidence-based-medicine1orthopedics1trauma1neonatology1psychiatry1internal-medicine1